Steve Sabus has served as our Chief Commercial Officer since December 2022. Prior to joining Syndax, Mr. Sabus served as Chief Commercial Officer at Turning Point Therapeutics before its acquisition by BMS. Before Turning Point, Mr. Sabus held senior commercial roles at Astellas Pharma for over 15 years, most recently serving as Senior Vice President, Head of Oncology. Earlier in his tenure at Astellas, Mr. Sabus headed the U.S. Medical Specialties business unit where he designed commercial strategies to extend the portfolio and increase market impact across therapeutic areas. Additionally, he was the General Manager of Astellas Canada, where his team launched Xospata®. Before Astellas, Mr. Sabus spent 16 years at Johnson & Johnson in commercial roles of increasing responsibility. Mr. Sabus received his Bachelor of Arts in Marketing & Sales Management at the University of Northern Iowa.